{"result": {"id": "2c380a47-fb9d-4257-bfe3-1d0f61b3b056", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Cardiovascular Research Community: Key Entities and Their Impact\",\n    \"summary\": \"This community is centered around cardiovascular research, with key entities including researchers like EslER M, GRANGER CB, and institutions such as the New England Journal of Medicine. The relationships within this community highlight collaborations on studies related to hypertension, atrial fibrillation, and other cardiovascular conditions. The New England Journal of Medicine serves as a central node, publishing significant research from many of these entities.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The high impact severity rating reflects the community's significant contributions to cardiovascular research and its potential to influence medical practices and patient outcomes globally.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of the New England Journal of Medicine\",\n            \"explanation\": \"The New England Journal of Medicine (N Engl J Med) is a pivotal entity in this community, serving as a primary publication venue for high-impact cardiovascular research. Many researchers, including GRANGER CB, ANTZ M, and others, have published their findings here, underscoring the journal's role in disseminating critical medical knowledge. [Data: Entities (2769), Relationships (3192, 3200, 3201, 3202, 3203, +more)]\"\n        },\n        {\n            \"summary\": \"Collaborative Research on Atrial Fibrillation\",\n            \"explanation\": \"A significant portion of the community's research focuses on atrial fibrillation, with researchers like GRANGER CB, ALEXANDER JH, and MCMURRAY JJ collaborating on studies comparing treatments such as Apixaban and Warfarin. These collaborations highlight the community's commitment to advancing treatment options for atrial fibrillation patients. [Data: Entities (3022, 3047, 3048), Relationships (3189, 3188, 3190, 3191)]\"\n        },\n        {\n            \"summary\": \"Focus on Hypertension and Cardiovascular Disease\",\n            \"explanation\": \"Researchers such as EslER M and WU S are deeply involved in studies on hypertension and its cardiovascular implications. Their work, often published in prestigious journals, contributes to a better understanding of hypertension mechanisms and treatment strategies. [Data: Entities (2785, 2275), Relationships (2932, 2543)]\"\n        },\n        {\n            \"summary\": \"International Collaborations and Studies\",\n            \"explanation\": \"The community includes international collaborations, such as the ONTARGET study involving researchers like YUSUFS and TEOKK, focusing on cardiovascular treatments. These global efforts underscore the community's wide-reaching impact on cardiovascular health. [Data: Entities (2737, 2738, 2739), Relationships (2881, 2882)]\"\n        },\n        {\n            \"summary\": \"Innovations in Heart Failure Treatment\",\n            \"explanation\": \"Research on heart failure treatments, including studies on angiotensin-neprilysin inhibition by researchers like PACKER M and LEWIS EF, represents a key area of innovation within the community. These studies aim to improve outcomes for heart failure patients through novel therapeutic approaches. [Data: Entities (3413, 3416), Relationships (3489, 3491)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751560525, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 681, "prompt_tokens": 8166, "total_tokens": 8847, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1664}, "prompt_cache_hit_tokens": 1664, "prompt_cache_miss_tokens": 6502}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n2785,ESLER M,\"ESLER M is a researcher specializing in hypertension and cardiovascular alterations, with a focus on evaluating elevated heart rate as a potential biomarker of the sympathetic nervous system in essential hypertension. Their work bridges clinical and physiological research, aiming to better understand the mechanisms underlying hypertension and its associated cardiovascular effects.\",2\n2769,N ENGLJ MED,\"The *New England Journal of Medicine (N Engl J Med)* is a prestigious medical journal that publishes high-quality research articles on a wide range of medical topics. It covers diverse areas such as cardiovascular diseases (including atrial fibrillation and hypertension), endocrine disorders (such as pheochromocytoma and paraganglioma), and nephrology (e.g., studies on aliskiren combined with losartan in type 2 diabetes and nephropathy, published in 2008). The journal has also featured research on acute clinical conditions, including rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. Known for its rigorous peer-review process and influential publications, *The New England Journal of Medicine* is a leading source of medical research and clinical practice advancements.\",49\n3022,GRANGER CB,\"**GRANGER CB** is a researcher involved in studies comparing Apixaban and Warfarin in patients with atrial fibrillation. The research focuses on evaluating the efficacy, safety, or other comparative aspects of these two anticoagulant medications specifically within the context of atrial fibrillation patients. The descriptions provided are consistent and reinforce GRANGER CB's role in this area of study.\",4\n3052,ANTZ M,A researcher involved in studies on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation>,1\n3053,KIRCHHOF P,A researcher involved in studies on early rhythm-control therapy in patients with atrial fibrillation>,1\n3054,CAMM AJ,A researcher involved in studies on early rhythm-control therapy in patients with atrial fibrillation>,1\n3055,GOETTE A,A researcher involved in studies on early rhythm-control therapy in patients with atrial fibrillation>,1\n3056,ROSEI EA,A researcher involved in studies on the management of hypertensive patients with elevated heart rate>,1\n3057,CASIGLIA E,A researcher involved in studies on the management of hypertensive patients with elevated heart rate>,1\n3059,DASBISWAS A,A researcher involved in studies on heart rate in hypertension>,1\n3060,SATHYAMURTHY I,A researcher involved in studies on heart rate in hypertension>,1\n3061,PISANO A,A researcher involved in studies on sympathetic nerve traffic activation in essential hypertension>,1\n3063,LAMBERT G,A researcher involved in studies on the evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension>,1\n3064,ESLER D,A researcher involved in studies on the evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension>,1\n3066,ZHENG M,A researcher involved in studies on the effect of resting heart rate on the risk of all-cause death in Chinese patients with hypertension>,1\n3070,KOMAJDAM,A researcher involved in studies on Ivabradine and outcomes in chronic heart failure>,1\n3072,LIN SI,A researcher involved in studies on optimal heart rate control in decompensated heart failure with reduced ejection fraction>,1\n3073,KAO YC,A researcher involved in studies on optimal heart rate control in decompensated heart failure with reduced ejection fraction>,1\n3075,CUCHERAT M,\"CUCHERAT M is a researcher specializing in cardiovascular studies, with a focus on investigating the quantitative relationship between resting heart rate reduction and the extent of clinical benefits in patients who have experienced a myocardial infarction (post-MI). Their work involves analyzing how reducing heart rate can improve clinical outcomes for post-MI patients, aiming to quantify the magnitude of these benefits. This research contributes to a deeper understanding of heart rate management strategies in post-MI care.\",1\n3324,ANDERSON CS,\"**ANDERSON CS** is a researcher who has focused on studying rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. Their work also extends to broader investigations into rapid blood pressure management in stroke patients, indicating a specialization in acute cerebrovascular conditions and hemodynamic interventions. This combined expertise highlights their involvement in critical care research aimed at improving outcomes for individuals experiencing severe stroke-related complications.\",1\n3338,QURESHI AI,\"Qureshi AI studied intensive blood-pressure lowering in patients with acute cerebral hemorrhage\"\"\",1\n3791,NEUMANN HPH,A researcher involved in studies on pheochromocytoma and paraganglioma,1\n3809,ENGC,A researcher co-authoring studies on pheochromocytoma and paraganglioma,1\n3393,PARADISE-MI TRIAL,A clinical trial investigating the effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction>,7\n3048,MCMURRAY JJ,\"**MCMURRAY JJ** is a researcher primarily focused on cardiovascular studies, with notable involvement in clinical trials comparing different treatments for atrial fibrillation and heart failure. Specifically, McMurray has contributed to research comparing **Apixaban and Warfarin** in patients with atrial fibrillation, as well as studies evaluating the efficacy of **angiotensin-neprilysin inhibition versus enalapril** in heart failure. His work spans multiple aspects of cardiovascular treatment, emphasizing advancements in anticoagulation therapy for atrial fibrillation and innovative approaches to managing heart failure. Collectively, his research highlights a commitment to improving therapeutic outcomes in cardiovascular medicine.\",3\n2989,BLAZING MA,Blazing MA is a researcher involved in studying ezetimibe added to statin therapy after acute coronary syndromes,2\n2990,GIUGLIANO RP,\"GIUGLIANO RP is a researcher with a focus on cardiovascular and anticoagulant studies. Their work includes comparing the efficacy of Edoxaban and Warfarin in patients with atrial fibrillation, as well as broader research on anticoagulants for atrial fibrillation. Additionally, GIUGLIANO RP has investigated the effects of adding ezetimibe to statin therapy following acute coronary syndromes. Their research spans multiple areas within cardiovascular medicine, including anticoagulation strategies and lipid management in high-risk patients.\",7\n2991,SABATINE MS,Sabatine MS is a researcher involved in studying evolocumab and clinical outcomes in patients with cardiovascular disease,2\n2992,KEECH AC,Keech AC is a researcher involved in studying evolocumab and clinical outcomes in patients with cardiovascular disease,2\n3049,RUFF CT,\"**RUFF CT** is a researcher involved in studies focused on the treatment of atrial fibrillation, particularly comparing the efficacy and outcomes of **Edoxaban** and **Warfarin** in patients with this condition. Their work contributes to the broader field of atrial fibrillation treatment research, aiming to evaluate and improve therapeutic options for affected individuals.\",2\n3050,BRAUNWALD E,\"**BRAUNWALD E** is a researcher known for their involvement in studies related to the treatment of atrial fibrillation. Their work includes comparative research between **Edoxaban** and **Warfarin** in patients with this condition, contributing to advancements in atrial fibrillation treatment strategies. Overall, BRAUNWALD E's research focuses on improving therapeutic outcomes for individuals with atrial fibrillation through clinical studies and drug comparisons.\",2\n3399,PFEFFER MA,Researcher involved in studies on angiotensin receptor-neprilysin inhibition in acute myocardial infarction>,1\n3400,MEHRAN R,Researcher involved in the PARADISE-MI trial>,1\n3413,PACKER M,Researcher involved in studies on angiotensin-neprilysin inhibition>,1\n3414,DESAI AS,Researcher involved in studies on angiotensin-neprilysin inhibition>,1\n3416,LEWIS EF,\"**LEWIS EF** is a researcher primarily focused on cardiovascular studies, with a particular emphasis on heart failure and related treatments. Their work involves investigating the effects of angiotensin receptor-neprilysin inhibition, a therapeutic approach for managing heart failure. Additionally, they study ejection fraction, a key metric in assessing heart function and the severity of heart failure. Their research contributes to a deeper understanding of both pharmacological interventions and physiological markers in cardiovascular health.\",1\n3417,STEG PG,\"STEG PG is a researcher who has been involved in multiple clinical studies, including research on icosapent ethyl for the treatment of hypertriglyceridemia. Additionally, STEG PG has contributed to the PARADISE-MI trial, which focuses on cardiovascular outcomes. Their work spans both lipid metabolism and cardiovascular disease research, demonstrating expertise in these interconnected fields.\",1\n2297,LANCET REG HEALTH WEST PAC,\"A regional health journal that published a study on hypertension and cardiovascular disease risk\"\"\",2\n2275,WU S,\"WU S is a researcher specializing in hypertension and cardiovascular disease risk, with a focus on Chinese populations. One of their notable contributions includes being an author of a randomized, multicenter, double-blind, noninferiority trial published in *Circulation: Cardiovascular Quality and Outcomes* in 2022, which compared the efficacy of Chinese herbal medicine with losartan for treating mild essential hypertension. Additionally, WU S has conducted research on isolated diastolic hypertension and its association with cardiovascular events, further contributing to the understanding of hypertension-related risks in specific demographic groups. Their work demonstrates a commitment to investigating both traditional and conventional treatments for hypertension while addressing cardiovascular outcomes.\",5\n3614,GUOJ,\"GuoJ is an author of a meta-analysis and systematic review on the relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD\"\"\",2\n3615,WU J,\"WU J is a researcher who has contributed to multiple studies across different medical fields. They are a co-author of a study examining the prevalence of hyperuricemia among Chinese adults, focusing on metabolic health. Additionally, WU J has authored research investigating the correlation between inhaled long-acting bronchodilators and adverse cardiovascular outcomes in patients with stable chronic obstructive pulmonary disease (COPD), highlighting their work in respiratory and cardiovascular health. Their diverse research contributions demonstrate expertise in both metabolic and pulmonary conditions.\",5\n2276,HUANG M,\"Huang M is a researcher who conducted a systematic review and meta-analysis on isolated diastolic hypertension and cardiovascular events.\"\"\",1\n2329,XU Y,\"A researcher involved in a study on hypertension and cardiovascular disease risk\"\"\",1\n2330,ZHENG R,\"A researcher involved in a study on hypertension and cardiovascular disease risk\"\"\",1\n3047,ALEXANDER JH,\"**ALEXANDER JH** is a researcher primarily focused on studies related to the treatment of atrial fibrillation. His work includes comparative research between Apixaban and Warfarin, two anticoagulant medications used in managing atrial fibrillation patients. His contributions in this field highlight his involvement in advancing understanding and treatment options for this cardiac condition.\",2\n3067,ZHANG M,\"ZHANG M is a researcher who has contributed to significant studies in the field of public health and epidemiology, particularly focusing on rural Chinese populations. As the lead author of a study on hyperuricemia prevalence among Chinese adults, ZHANG M has explored the distribution and implications of this condition in the demographic. Additionally, ZHANG M has been involved in research examining the association between resting heart rate and cardiovascular disease mortality, comparing outcomes in hypertensive and normotensive individuals within rural Chinese communities. These studies highlight ZHANG M's expertise in cardiovascular health and metabolic disorders, with a focus on understanding risk factors and health disparities in specific populations.\",5\n3079,J CARDIOL,A medical journal publishing research articles on cardiology>,1\n3616,YE Y,\"Ye Y is a co-author of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD\"\"\",1\n3258,LI C,\"Li C is a researcher who has contributed to multiple studies across different areas of health and medicine. They are a co-author of a study examining the correlation between inhaled long-acting bronchodilators and adverse cardiovascular outcomes in patients with stable chronic obstructive pulmonary disease (COPD). Additionally, Li C has been involved in research focused on hypertension among Chinese adolescents. Their work spans both respiratory and cardiovascular health, demonstrating a broad research interest in chronic conditions affecting diverse populations.\",1\n2853,J CARDIOVASC PHARMACOL,\"**J CARDIOVASC PHARMACOL** (Journal of Cardiovascular Pharmacology) is a medical journal that has published significant research in the field of cardiovascular pharmacology. In 2016, it featured a study on third-generation mineralocorticoid receptor antagonists, highlighting advancements in cardiovascular therapeutics. Additionally, the journal published a network meta-analysis by Wu J, which examined the relationship between bronchodilators and cardiovascular outcomes, further contributing to the understanding of pharmacological interventions in cardiovascular medicine. Together, these publications underscore the journal's role in disseminating cutting-edge research on drug therapies for cardiovascular conditions.\",1\n4226,CHINESE MEDICAL ASSOCIATION RHEUMATOLOGY BRANCH,,1\n4219,ZHU X,\"Co-author of a study on hyperuricemia prevalence among Chinese adults\"\"\",1\n2022,南京医科大学第一附属医院,南京医科大学第一附属医院（The First Affiliated Hospital of Nanjing Medical University）是南京医科大学的一所附属医院。该医院设有风湿免疫科（rheumatology and immunology department），医生王强（Wang Qiang）在此科室工作。作为南京医科大学的附属机构，该医院承担医疗、教学和科研等多重职能，致力于提供高水平的医疗服务。,2\n2024,黄峻,\"黄峻 is a medical professional affiliated with both 南京医科大学第一附属医院 (The First Affiliated Hospital of Nanjing Medical University) and 江苏省人民医院 (Jiangsu Provincial People's Hospital). In addition to his clinical work, he is also a researcher involved in studies focusing on the heart rate status of Chinese hypertensive patients, contributing to advancements in cardiovascular health research. His dual roles as a practitioner and researcher highlight his expertise in the medical field, particularly in hypertension and cardiac health.\",3\n3017,SHI S,A researcher involved in epidemiological studies on atrial fibrillation in China,3\n3039,ZHAO Q,\"ZHAO Q is a researcher involved in cardiovascular and epidemiological studies in China. Their work includes investigating the effect of resting heart rate on the risk of all-cause death among Chinese patients with hypertension, as well as participating in an epidemiological study on atrial fibrillation in the Chinese population. Their research contributes to a better understanding of cardiovascular health and risk factors in hypertensive and arrhythmia patients.\",2\n3068,HAN C,\"HAN C is a researcher with expertise in cardiovascular disease and its associated risk factors. They have been involved in studies examining the relationship between resting heart rate and cardiovascular disease mortality in both hypertensive and normotensive populations within rural Chinese communities. Additionally, HAN C has contributed as an author to research focusing on cardiovascular disease and its risk factors in patients with rheumatic conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Their work spans both general and specific populations, highlighting their broad research interests in cardiovascular health.\",4\n3638,ROBINSON DW,\"Robinson DW is a co-author of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\"\"\",1\n3639,HACKETT MV,\"Hackett MV is a co-author of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\"\"\",1\n3652,J RHEUMATOL,\"Journal of Rheumatology is a medical journal that published Han C's study on cardiovascular risks in rheumatic diseases\"\"\",1\n2023,江苏省人民医院,A major hospital in Jiangsu Province,1\n2737,ONTARGET INVESTIGATORS,\"ONTARGET Investigators is a research group involved in studies on telmisartan and ramipril in patients at high risk for vascular events.\"\"\",3\n2738,YUSUFS,\"YusufS is a researcher associated with the ONTARGET study on telmisartan and ramipril.\"\"\",1\n2739,TEOKK,\"TeoKK is a researcher involved in the ONTARGET study on cardiovascular treatments.\"\"\",1\n2928,BOLIGNANO D,\"**BOLIGNANO D** is a researcher known for their work in the field of hypertension, particularly focusing on the activation of sympathetic nerve traffic in essential hypertension. Additionally, they contributed as one of the authors of a review on baroreflex stimulation as a treatment for resistant hypertension, which was published in *Rev CardiovascMed* in 2018. Their expertise spans both the physiological mechanisms of hypertension and potential therapeutic interventions.\",2\n2930,REV CARDIOVASCMED,\"A medical journal that published the review on baroreflex stimulation for treating resistant hypertension.\"\"\",2\n2947,LAI X,\"One of the authors of a randomized, multicenter, double-blind, noninferiority trial comparing Chinese herbal medicine with losartan for mild essential hypertension, published in CircCardiovascQualOutcomes in 2022.\"\"\",1\n2949,CIRCCARDIOVASCQUALOUTCOMES,\"A medical journal that published the randomized trial comparing Chinese herbal medicine with losartan for mild essential hypertension.\"\"\",3\n2948,DONG Z,\"One of the authors of a randomized, multicenter, double-blind, noninferiority trial comparing Chinese herbal medicine with losartan for mild essential hypertension, published in CircCardiovascQualOutcomes in 2022.\"\"\",1\n2988,CANNON CP,Cannon CP is a researcher involved in studying ezetimibe added to statin therapy after acute coronary syndromes,2\n3038,TANG Y,Researcher involved in atrial fibrillation epidemiological study in China,1\n2753,PARVING H,\"Parving H is a researcher involved in trials of aliskiren for type 2 diabetes and its cardiorenal outcomes.\"\"\",2\n2754,BRENNER BM,\"Brenner BM is a researcher who co-authored studies on aliskiren and its effects on type 2 diabetes.\"\"\",1\n2929,COPPOLINO G,\"One of the authors of a review on baroreflex stimulation for treating resistant hypertension, published in Rev CardiovascMed in 2018.\"\"\",1\n3051,STEFFEL J,A researcher involved in studies on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation>,2\n3082,EUROPACE,,1\n3058,DALAL J,A researcher involved in studies on heart rate in hypertension>,2\n3076,INT J HYPERTENS,A medical journal publishing research articles on hypertension>,1\n3062,SERAVALLE G,A researcher involved in studies on the sympathetic nervous system and hypertension>,2\n3077,AUTON NEUROSCI,A medical journal publishing research articles on autonomic neuroscience>,1\n3071,TSAI ML,A researcher involved in studies on optimal heart rate control in decompensated heart failure with reduced ejection fraction>,2\n3080,MEDICINA (KAUNAS),A medical journal publishing research articles on various medical topics>,1\n3653,INT J CHRON OBSTRUCT PULMON DIS,,1\n4116,王嫱,A professional working in the rheumatology and immunology department at the First Affiliated Hospital of Nanjing Medical University,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n2932,JAMA NETW OPEN,ESLER M,Esler M contributed to research published in JAMA Netw Open,60\n3192,N ENGLJ MED,GRANGER CB,Granger CB published research in N EnglJ Med,53\n3200,N ENGLJ MED,ANTZ M,Antz M published research in N EnglJ Med,50\n3201,N ENGLJ MED,KIRCHHOF P,Kirchhof P published research in N EnglJ Med,50\n3202,N ENGLJ MED,CAMM AJ,Camm AJ published research in N EnglJ Med,50\n3203,N ENGLJ MED,GOETTE A,Goette A published research in N EnglJ Med,50\n3205,N ENGLJ MED,ROSEI EA,Rosei EA published research in N EnglJ Med,50\n3206,N ENGLJ MED,CASIGLIA E,Casiglia E published research in N EnglJ Med,50\n3208,N ENGLJ MED,DASBISWAS A,Dasbiswas A published research in N EnglJ Med,50\n3209,N ENGLJ MED,SATHYAMURTHY I,Sathyamurthy I published research in N EnglJ Med,50\n3214,N ENGLJ MED,PISANO A,Pisano A published research in N EnglJ Med,50\n3218,N ENGLJ MED,LAMBERT G,Lambert G published research in N EnglJ Med,50\n3219,N ENGLJ MED,ESLER D,Esler D published research in N EnglJ Med,50\n3222,N ENGLJ MED,ZHENG M,Zheng M published research in N EnglJ Med,50\n3227,N ENGLJ MED,KOMAJDAM,Komajdam published research in N EnglJ Med,50\n3230,N ENGLJ MED,LIN SI,Lin SI published research in N EnglJ Med,50\n3231,N ENGLJ MED,KAO YC,Kao YC published research in N EnglJ Med,50\n3233,N ENGLJ MED,CUCHERAT M,Cucherat M published research in N EnglJ Med,50\n3440,N ENGLJ MED,ANDERSON CS,Anderson CS published research in the New England Journal of Medicine,50\n3441,N ENGLJ MED,QURESHI AI,Qureshi AI published research in the New England Journal of Medicine,50\n3771,N ENGLJ MED,NEUMANN HPH,Neumann HPH published a study in N EnglJ Med,50\n3772,N ENGLJ MED,ENGC,EngC co-authored research published in N EnglJ Med,50\n3486,PARADISE-MI TRIAL,MCMURRAY JJ,McMurray JJ was involved in studies related to the PARADISE-MI trial,10\n3126,BLAZING MA,GIUGLIANO RP,Blazing MA and Giugliano RP collaborated on research about ezetimibe added to statin therapy after acute coronary syndromes,9\n3127,GIUGLIANO RP,SABATINE MS,Sabatine MS and Giugliano RP collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease,9\n3128,GIUGLIANO RP,KEECH AC,Giugliano RP and Keech AC collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease,9\n3190,GIUGLIANO RP,RUFF CT,Co-authors on atrial fibrillation treatment study,9\n3191,GIUGLIANO RP,BRAUNWALD E,Co-authors on atrial fibrillation treatment study,9\n3487,PARADISE-MI TRIAL,PFEFFER MA,Pfeffer MA was a researcher involved in the PARADISE-MI trial,8\n3488,PARADISE-MI TRIAL,MEHRAN R,Mehran R was a researcher involved in the PARADISE-MI trial,8\n3489,PARADISE-MI TRIAL,PACKER M,Packer M was involved in related research on angiotensin-neprilysin inhibition,8\n3490,PARADISE-MI TRIAL,DESAI AS,Desai AS was involved in related research on angiotensin-neprilysin inhibition,8\n3491,PARADISE-MI TRIAL,LEWIS EF,Lewis EF was involved in research on angiotensin receptor-neprilysin inhibition,8\n3492,PARADISE-MI TRIAL,STEG PG,Steg PG was a researcher involved in the PARADISE-MI trial,8\n2543,LANCET REG HEALTH WEST PAC,WU S,Wu S co-authored a study published in Lancet Reg Health West Pac,7\n3189,GRANGER CB,MCMURRAY JJ,Co-authors on atrial fibrillation treatment study,7\n3658,GUOJ,WU J,Both are authors of studies on the relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD,7\n2522,WU S,HUANG M,Both researchers studied isolated diastolic hypertension and its cardiovascular implications.,6\n2563,WU S,XU Y,Wu S and Xu Y co-authored a study on hypertension guidelines,6\n2564,WU S,ZHENG R,Wu S and Zheng R co-authored a study on hypertension guidelines,6\n3188,GRANGER CB,ALEXANDER JH,Co-authors on atrial fibrillation treatment study,6\n3240,ZHANG M,J CARDIOL,Zhang M published research in J Cardiol,6\n3660,WU J,YE Y,Both are co-authors of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD,6\n3661,WU J,LI C,Both are co-authors of a study on the correlation of inhaled long-acting bronchodilators with adverse cardiovascular outcomes in patients with stable COPD,6\n3662,WU J,J CARDIOVASC PHARMACOL,Wu J's network meta-analysis was published in the Journal of Cardiovascular Pharmacology,6\n4140,ZHANG M,CHINESE MEDICAL ASSOCIATION RHEUMATOLOGY BRANCH,The Chinese Medical Association Rheumatology Branch published guidelines citing Zhang M's research,6\n4141,ZHANG M,ZHU X,Co-authors of a study on hyperuricemia prevalence,6\n2349,南京医科大学第一附属医院,黄峻,黄峻 is affiliated with 南京医科大学第一附属医院,5\n3177,SHI S,LANCET REG HEALTH WEST PAC,Published an epidemiological study on atrial fibrillation in China in Lancet Reg Health West Pac,5\n3179,SHI S,ZHAO Q,Co-authors on atrial fibrillation study in China,5\n3685,HAN C,ROBINSON DW,\"Both are co-authors of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\",5\n3686,HAN C,HACKETT MV,\"Both are co-authors of a study on cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis\",5\n3687,HAN C,J RHEUMATOL,Han C's study on rheumatic diseases was published in the Journal of Rheumatology,5\n2350,江苏省人民医院,黄峻,黄峻 is affiliated with 江苏省人民医院,4\n2881,ONTARGET INVESTIGATORS,YUSUFS,YusufS is a key researcher in the ONTARGET study.,4\n2882,ONTARGET INVESTIGATORS,TEOKK,TeoKK contributed to the ONTARGET study on cardiovascular treatments.,4\n3084,BOLIGNANO D,REV CARDIOVASCMED,Bolignano D is one of the authors of a study published in Rev CardiovascMed.,4\n3098,LAI X,CIRCCARDIOVASCQUALOUTCOMES,Lai X is one of the authors of a study published in CircCardiovascQualOutcomes.,4\n3099,DONG Z,CIRCCARDIOVASCQUALOUTCOMES,Dong Z is one of the authors of a study published in CircCardiovascQualOutcomes.,4\n3124,CANNON CP,BLAZING MA,Cannon CP and Blazing MA collaborated on research about ezetimibe added to statin therapy after acute coronary syndromes,4\n3129,SABATINE MS,KEECH AC,Sabatine MS and Keech AC collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease,4\n3178,SHI S,TANG Y,Co-authors on atrial fibrillation study in China,4\n2897,PARVING H,BRENNER BM,Parving H and Brenner BM co-authored studies on aliskiren for type 2 diabetes.,3\n3085,COPPOLINO G,REV CARDIOVASCMED,Coppolino G is one of the authors of a study published in Rev CardiovascMed.,3\n3234,STEFFEL J,EUROPACE,Steffel J published research in Europace,3\n3236,DALAL J,INT J HYPERTENS,Dalal J published research in Int J Hypertens,3\n3238,SERAVALLE G,AUTON NEUROSCI,Seravalle G published research in Auton Neurosci,3\n3242,TSAI ML,MEDICINA (KAUNAS),Tsai ML published research in Medicina (Kaunas),3\n3659,GUOJ,INT J CHRON OBSTRUCT PULMON DIS,GuoJ's meta-analysis was published in the International Journal of Chronic Obstructive Pulmonary Disease,3\n4078,南京医科大学第一附属医院,王嫱,Wang Qiang works in the rheumatology and immunology department at the First Affiliated Hospital of Nanjing Medical University,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_899e2b150f7da2a36f0b2f0419762e0d434d75813fb81dfcb2eebb463a63b86d_v2"}